Q2 FY2026 · ended Jun 30, 2026 · Revenue $33.66M, +114.2% YoY · Filed Aug 13, 2026
ARS Pharmaceuticals, Inc. (SPRY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $33.7 million and a net loss of $62.3 million. Free cash flow was -$60.9 million. As of Jun 30, 2026 it held $143.8 million in cash and investments and $96.7 million in total debt.
Revenue
$33.66M
+114.2% vs year-ago quarter
Net income
$-62.34M
-38.9% vs year-ago quarter
Operating cash flow
$-60.93M
-53.9% vs year-ago quarter
Free cash flow
$-60.93M
-53.7% vs year-ago quarter
EPS
$-0.63
-37.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
99.45M
+0.6% vs year-ago quarter
Net cash
$47.17M
Q2 FY2026
Operating margin
-185.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671858
- Former names
- Silverback Therapeutics, Inc. (until Nov 8, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $33.7M | $22.7M | $28.1M | $32.5M | $15.7M |
| Operating income | -$61.5M | -$60.1M | -$41.5M | -$53.2M | -$47.6M |
| Net income | -$62.3M | -$60.6M | -$41.3M | -$51.2M | -$44.9M |
| Diluted EPS | -$0.63 | -$0.61 | -$0.42 | -$0.52 | -$0.46 |
| Operating cash flow | -$60.9M | -$44.9M | -$43.5M | -$47.0M | -$39.6M |
| Free cash flow | -$60.9M | -$44.9M | -$43.5M | -$47.2M | -$39.6M |
| Total assets | $249.5M | $287.6M | $327.7M | $372.8M | $313.5M |
| Total liabilities | $237.0M | $226.3M | $213.4M | $225.1M | $121.2M |
| Stockholders' equity | $12.5M | $61.3M | $114.3M | $147.7M | $192.3M |
| Cash and investments | $143.8M | $201.0M | $245.0M | $288.2M | $240.1M |
| Total debt | $96.7M | $96.5M | $96.4M | $97.8M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 547 ARS Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.